Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis

References

• World Health Organization. WHO Coronavirus (COVID-19) Dashboard. (2022). [cited]. Available from: https://covid19.who.int/.
   Google Scholar
• Data OWi. Estimated Cases by Variant. (2022). [cited]. Available from: Estimated Cases by Variant.
   Google Scholar
• Shrotri M, Swinnen T, Kampmann B, et al. An interactive website tracking COVID-19 vaccine development. The Lancet Global Health. 2021;9(5):e590–e592.
   PubMed Web of Science ®Google Scholar
• Zheng C, Shao W, Chen X, et al. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252–260.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet. 2021;397(10277):881–891.
   PubMed Web of Science ®Google Scholar
• World Health Organization. SARS-CoV-2 variants, working definitions and actions taken. (2022). [cited]. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants.
   Google Scholar
• Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet. 2021;397(10282):1351–1362.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885–1898.
   PubMed Web of Science ®Google Scholar
• Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. The Lancet. 2021;398(10317):2173–2184.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N Engl J Med. 2022;386(9):847–860.
   PubMed Web of Science ®Google Scholar
• Cascini F, Pantovic A, Al-Ajlouni Y, et al. Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: A systematic review. EClinicalMedicine. 2021;40:101113.
   PubMedGoogle Scholar
• McIntyre PB, Aggarwal R, Jani I, et al. COVID-19 vaccine strategies must focus on severe disease and global equity. The Lancet. 2022;399(10322):406–410.
   PubMed Web of Science ®Google Scholar
• Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 delta variant in Qatar. Nat Med. 2021;27(12):2136–2143.
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar. N Engl J Med. 2022;386(19):1804–1816.
   PubMed Web of Science ®Google Scholar
• Hitchings MDT, Ranzani OT, Torres MSS, et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 gamma variant transmission in Manaus. Brazil: a test-negative case-control study. Lancet Reg Health Am. 2021 Sep;1:100025.
   PubMedGoogle Scholar
• Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. Br Med J. 2021 Dec 15;375:e068848.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. [cited]. Available from: https://www.ohri.ca//programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Sheikh A, Kerr S, Woolhouse M, et al. Severity of Omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis. 2022 Apr 22;22(7):959–966.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen Z, Azman AS, et al. Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants induced by natural infection or vaccination: a systematic review and pooled analysis. Clin Infect Dis. 2022;74(4):734–742.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen L, Yin S, et al. The third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. Emerg Microbes Infect. 2022;11(1):1524–1536.
   PubMed Web of Science ®Google Scholar
• GeurtsvanKessel CH, Geers D, Schmitz KS, et al. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 2022;7(69):eabo2202.
   PubMed Web of Science ®Google Scholar
• Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27(9):1525–1529.
   PubMed Web of Science ®Google Scholar
• Campos GRF, Almeida NBF, Filgueiras PS, et al. Booster dose of BNT162b2 in a CoronaVac primary vaccination protocol improves neutralization of SARS-CoV-2 Omicron variant. medRxiv. 2022:2022.03.24.22272904.
   Google Scholar
• Assawakosri S, Kanokudom S, Chansaenroj J, et al. Persistence of immunity against Omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination. Int J Infect Dis. 2022;122:793–801.
   PubMed Web of Science ®Google Scholar
• Au WY, Cheung PP. Effectiveness of heterologous and homologous COVID-19 vaccine regimens: living systematic review with network meta-analysis. Br Med J. 2022 May 31;377:e069989.
   PubMedGoogle Scholar
• Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2022;3(1):e52–e61.
   PubMedGoogle Scholar
• Khoury DS, Steain M, Triccas JA, et al. A meta-analysis of early results to predict vaccine efficacy against Omicron. medRxiv. 2021:2021.12.13.21267748.
   Google Scholar
• Ai J, Wang X, He X, et al. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe. 2022;30(8):1077–1083.e4.
   PubMed Web of Science ®Google Scholar
• Wang J, Tong Y, Li D, et al. The impact of age difference on the efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12:758294.
   PubMed Web of Science ®Google Scholar
• Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by COVID-19 vaccines. N Engl J Med. 2022;386(4):340–350.
   PubMed Web of Science ®Google Scholar
• McDonald I, Murray SM, Reynolds CJ, et al. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines. 2021;6(1):74.
   PubMed Web of Science ®Google Scholar
• Naranbhai V, Garcia-Beltran WF, Chang CC, et al. Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 vaccines. J Infect Dis. 2022;225(7):1141–1150.
   PubMed Web of Science ®Google Scholar
• Khong K-W, Liu D, Leung K-Y, et al. Antibody response of combination of BNT162b2 and CoronaVac platforms of COVID-19 vaccines against Omicron variant. Vaccines (Basel). 2022;10(2):160.
   PubMed Web of Science ®Google Scholar
• Rotshild V, Hirsh-Raccah B, Miskin I, et al. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021;11(1):22777.
   PubMed Web of Science ®Google Scholar
• Liu Q, Qin C, Liu M, et al. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):132.
   PubMed Web of Science ®Google Scholar
• Prevention CfDCa. CDC recommends Pfizer Booster at 5 months, additional primary dose for certain immunocompromised Childre. Tuesday, January 4, 2022 [cited]. Available from: https://www.cdc.gov/media/releases/2022/s0104-Pfizer-Booster.html.
   Google Scholar
• Agency UHS. SARS-CoV-2 variants of concern and variants under investigation in England: omicron VOC-21NOV-01 (B.1.1.529) update on cases, S gene target failure and risk assessment. . December 8, 2021 [cited December 8, 2021]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1039644/Omicron_SGTF_case_update_FINAL.pdf.
   Google Scholar
• Dai L, Gao L, Tao L, et al. Efficacy and safety of the RBD-dimer-based COVID-19 vaccine ZF2001 in adults. N Engl J Med. 2022;386(22):2097–2111.
   PubMed Web of Science ®Google Scholar
• Khobragade A, Bhate S, Ramaiah V, et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet. 2022;399(10332):1313–1321.
   PubMed Web of Science ®Google Scholar
• Zhu F, Zhuang C, Chu K, et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med. 2022;10(8):749–760.
   PubMed Web of Science ®Google Scholar